Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Recurrence 3Lymphoma, Non-Hodgkin 3Lymphoma 3Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

Rituximab 9ibrutinib 6acalabrutinib 6Cyclophosphamide 6zanubrutinib 4venetoclax 4fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Methotrexate 3Magnetic Resonance Spectroscopy 3Cytarabine 3Cyclosporine 3CT-P10 3Bendamustine Hydrochloride 3merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Vincristine 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Etoposide 2Doxorubicin 2Dexamethasone 2Calcium Dobesilate 2treosulfan 1pirtobrutinib 1palbociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × glofitamab × 30 days × Clear all
NCT07003295 2026-06-03

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

National Cancer Institute (NCI)

Phase 2 Recruiting
20 enrolled
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡